Redx Set To Be Taken Over By Redmile
Premium Of 210% For UK Biotech
Executive Summary
Ex-suitor Yesod seemed keen again but it looks as though Redx Pharma is about to be acquired by Redmile after the US healthcare investor upped its stake in the oncology and fibrotic diseases specialist.
You may also be interested in...
Revamped Redx’s New CEO Says Porcupine Inhibitor Trials 'Now On Track'
After regulatory talks, revamped Redx gets green light to resume clinical study of RXC004 in patients with advanced solid tumors, while sister porcupine inhibitor RXC006 is set to enter IPF trials in 2020, the biotech's CEO tells Scrip.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.